Table 1.
The clinico-pathologic characteristics of the study population
| Group 1 (n = 39) | Group 2 (n = 26) | P-value | |
|---|---|---|---|
| |
mean±SD (range)/n (%) |
mean±SD (range)/n (%) |
|
| Age, years |
49.64 ± 10.6 (21to 74) |
46.6 ± 7.7 (33 to 64) |
0.209 |
| Follow-up, months |
36.5 ± 26.3 (1.6 to 89.9) |
30.4 ± 21.9 (1.6 to 84.1) |
0.333 |
| Pathology |
|
|
0.446 |
| Infiltrating ductal carcinoma |
29 (74.4) |
19 (73.1) |
|
| Ductal carcinoma in situ |
8 (20.5) |
7 (26.9) |
|
| Infiltrating lobular carcinoma |
2 (5.1) |
0 |
|
| Tumor size, cm |
2.1 ± 0.9 (0.2 to 4.8) |
1.8 ± 0.9 (0.2 to 3.5) |
0.304 |
| Stage |
|
|
0.274 |
| 0 |
8 (20.5) |
7 (26.9) |
|
| I |
16 (41.0) |
13 (50.0) |
|
| IIA |
10 (25.6) |
3 (11.5) |
|
| IIB |
4 (10.3) |
3 (11.5) |
|
| IIIA |
1 (2.6) |
0 |
|
| T |
|
|
0.493 |
| Tis |
8 (20.5) |
7 (26.9) |
|
| T1 |
17 (43.6) |
13 (50.0) |
|
| T2 |
14 (35.9) |
6 (23.1) |
|
| N |
|
|
0.489 |
| N0 |
32 (82.0) |
23 (88.5) |
|
| N1 |
6 (15.4) |
3 (11.5) |
|
| N2 |
1 (2.6) |
0 |
|
| Adjuvant chemotherapy |
|
|
0.441 |
| No |
18 (46.2) |
18 (69.2) |
|
| CMFa |
12 (30.8) |
4 (15.4) |
|
| AC-Tb |
3 (7.7) |
1 (3.8) |
|
| TACc |
3 (7.7) |
2 (7.7) |
|
| FACd |
3 (7.7) |
1 (3.8) |
|
| Anti-hormone therapy |
|
|
0.548 |
| No |
8 (20.5) |
7 (26.9) |
|
| Yes |
31 (79.5) |
19 (73.1) |
|
| Radiotherapy |
|
|
0.411 |
| No |
38 (97.4) |
26 (100) |
|
| Yes |
1 (2.6) |
0 |
|
| Local recurrence |
|
|
|
| No |
39 (100) |
26 (100) |
|
| Yes |
0 |
0 |
|
| Regional Metastasis |
|
|
0.411 |
| No |
38 (97.4) |
26 (100) |
|
| Yes | 1 (2.6) | 0 |
aCMF:cyclophosphamide, methotraxate, flurouracil; bA, doxorubicin; C, cyclophosphamide; T, docetaxel; cT, docetaxel, A, doxorubicin, C, cyclophosphamide; dFAC: flurouracil, epirubicin, cyclophosphamide.